{"filings":[{"id":2466077,"accession_number":"0001193125-26-365132","cik":1657677,"company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","form_type":"8-K","filed_at":"2026-08-25T20:10:15+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Parabilis Medicines appoints Craig Tendler to board as independent Class II director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to nine; Craig Tendler, M.D., appointed Class II director on Aug 22, 2026, term to 2028.","Receives stock option for 20,294 shares at $39.36/share, vesting monthly over 3 years.","Annual retainer of $40,000 for board plus $7,500 for Science & Technology Committee service.","Tendler brings 30+ years oncology development incl. two decades at J&J; joins Science & Technology Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2226156,"accession_number":"0001193125-26-347869","cik":1657677,"company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","form_type":"8-K","filed_at":"2026-08-13T11:19:04+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Parabilis Q2 net loss $52.5M; $1.1B cash after $770.5M IPO; Regeneron deal up to $2.2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $52.5M in Q2 2026 vs $34.8M prior year; R&D $39.4M, G&A $11.7M.","Cash $1.1B as of June 30, 2026 (vs $27.7M Dec 31, 2025) after $770.5M IPO at $20.00/share; funds ops into 2030.","Regeneron collaboration: $125M received ($50M upfront + $75M equity); up to $2.2B milestones plus low double-digit tiered royalties for Antibody-Helicon Conjugates.","Zolucatetide: ESMO 2026 abstract accepted; FDA alignment Q4 2026; Phase 3 desmoid trial initiation H1 2027; FAP cohort H2 2026.","Leadership: Helen Ho (Chief Business & Strategy Officer), Tom Kotarakos (CFO), Alan M. Sebulsky to Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1000240,"accession_number":"0001193125-26-267550","cik":1657677,"company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","form_type":"8-K","filed_at":"2026-06-11T20:12:52+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Regeneron invests $75M in Parabilis at 10% discount to IPO price in concurrent private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchased 4,166,666 shares at 90% of $20 IPO price ($18/share); total $75M.","Private placement closed June 11, 2026, alongside IPO.","Regeneron granted piggyback registration rights on the shares.","Charter amended to authorize 600M voting and 200M non-voting common shares, eliminate preferred.","Transaction signals strategic backing from a major biopharma partner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}